Business Segments · Total segment depreciation and amortization
Oncology & Multispecialty — Total segment depreciation and amortization
McKesson Oncology & Multispecialty — Total segment depreciation and amortization decreased by 11.3% to $63.00M in Q4 2025 compared to the prior quarter.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ3 2024
Last reportedQ4 2025
Rolls up toD&A
How to read this metric
Rising levels often indicate significant recent capital investment, whereas declining levels may suggest aging assets or reduced investment intensity.
Detailed definition
The total non-cash expense allocated to the Oncology and Multispecialty segment related to the systematic write-down of...
Peer comparison
Standard across all capital-intensive industries; comparable to 'Segment D&A' reported by peers like Cencora or Cardinal Health.
Metric ID:
mck_segment_oncology_multispecialty_total_segment_depreciation_and_amortizationHistorical Data
4 periods
| Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|
| Value | $37.00M | $37.00M | $71.00M | $63.00M |
| QoQ Change | — | +0.0% | +91.9% | -11.3% |
| YoY Change | — | — | +91.9% | +70.3% |
Range$37.00M – $71.00M
Avg YoY Growth+81.1%
Median YoY Growth+81.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's oncology & multispecialty — total segment depreciation and amortization?
- McKesson (MCK) reported oncology & multispecialty — total segment depreciation and amortization of $63.00M in Q4 2025.
- What does oncology & multispecialty — total segment depreciation and amortization mean?
- The total non-cash cost of wearing out or using up assets within the Oncology and Multispecialty segment.